Prostate cancer (PCa) has become the most frequent type of cancer in men. Recent data
suggest that diabetic patients taking metformin have a lower incidence of certain cancer …

Abstract Purpose of Review Since epidemiological studies first demonstrated a potential
positive effect of metformin in reducing cancer incidence and mortality, there has been an …

Metformin, an oral biguanide used for first-line treatment of type 2 diabetes mellitus, has
attracted attention for its anti-proliferative and anti-cancer effects in several solid tumors …

Metformin, the first line pharmacotherapy for type 2 diabetes has demonstrated favourable
effects in prostate cancer (PCa) across a range of studies evaluating PCa patient outcomes …

Purpose Metformin is a commonly used medication for type II diabetes mellitus.
Epidemiologic studies have suggested a decreased relative risk of cancer with metformin …

By Anna Azvolinsky Already recommended as a first-line therapy for diabetic men
diagnosed with prostate cancer, metformin is one of the most widely prescribed drugs in the …

Abstract Background Prostate cancer (PCa) is characterized as the most frequent type of
cancer in males. Recent research has suggested patients who have diabetes mellitus taking …

Preclinical studies have suggested the antitumorigenic properties of metformin on prostate
cancer; results from epidemiological studies remain contradictory. We aim to investigate the …

Objectives Metformin has numerous antineoplastic effects including an AMP-activated
protein kinase–dependent mechanism, AMP-activated protein kinase–independent …

Purpose Observational studies report conflicting results on the association between
metformin exposure and prostate cancer outcomes. This meta-analysis summarizes studies …